All News
Filter News
Found 4,294 articles
-
Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
2/25/2020
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore the co-administration of SB 11285, Spring Bank’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced solid tumors.
-
MacroGenics Provides Update on Corporate Progress and 2019 Financial Results
2/25/2020
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2019.
-
Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results And Recent Business Developments
2/25/2020
Prescription Drug User Fee Act (PDUFA) date for rimegepant Zydis® orally dissolving tablet (ODT) set for 1Q2020 and Company prepared for commercialization
-
Magenta Conditioning Lead Clinical Candidate MGTA-117 Demonstrates Broad Tolerability and High Therapeutic Index in Non-human Primates
2/24/2020
Feb. 24, 2020 13:30 UTC – MGTA-117 ADC clinical candidate for conditioning showed broad tolerability and wide pre-clinical safety margins – – MGTA-117 demonstrated robust anti-tumor activity in xenograft models from patients with refractory leukemia – – Magenta plans to move MGTA-117 into the clinic with initial clinical data in 2021 – – Landmark data with tool CD117-ADC demonstrate first successful gene therapy transplant without chemotherapy in non-human primates, awar
-
Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference
2/21/2020
SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will present at LEERINK Partners 9th Annual Global Healthcare Conference (Lotte New York Palace Hotel, New York) on Thursday Feb 27 at 11:00-11:25 AM (Presentation Room Adams). The webcast will be available through http://wsw.com/webcast/svbleerink34/srne during the conference and for the following 96 days. The presentation will also be accessible on the company
-
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2019 Financial Results and Business Updates
2/21/2020
Mersana Therapeutics, Inc. (NASDAQ:MRSN), today announced that it will host a conference call and webcast on Friday, February 28, 2020 at 8:00 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2019 and provide business updates.
-
Seattle Genetics and Astellas' Padcev Wins Breakthrough Therapy Designation in Bladder Cancer
2/20/2020
Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer. -
The Phase II trial did not meet its primary endpoint.
-
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
2/19/2020
Feb. 19, 2020 13:12 UTC Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV ™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer - Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial - BOTHELL, Wash. & TOKYO--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
-
Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs
2/19/2020
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced a global license agreement with Seattle Genetics, Inc. to develop and commercialize novel antibody-drug conjugate (ADC) therapies using monoclonal antibodies developed by Five Prime.
-
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
2/19/2020
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEV™ (enfortumab vedotin-ejfv) in combination with Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA
-
Mersana Therapeutics to Present at Upcoming Investor Conferences
2/18/2020
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at two upcoming investor conferences.
-
Immunomedics Appoints Dr. Loretta Itri Chief Medical Officer
2/14/2020
Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the appointment of Loretta Itri, M.D. as chief medical officer (CMO), effective today.
-
Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results
2/14/2020
HOPKINTON, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the fourth quarter and year-ended December 31, 2019 and provided an update on recent corporate and clinical development highlights. “In January, we made the difficult decision to discontinue our development efforts
-
Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
2/13/2020
Feb. 13, 2020 13:00 UTC - FDA Action Date is August 20, 2020; Application Under FDA’s Real-Time Oncology Review (RTOR) and Orbis Pilot Programs - - Supported by Results from Pivotal HER2CLIMB Trial; First Investigational Therapy in a Pivotal Trial to Include Patients with Metastatic HER2-Positive Breast Cancer with Active Brain Metastases - BOTHELL, Wash.--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administ
-
Alligator Bioscience AB Year-end Report January-December 2019
2/12/2020
"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project and at year-end, the number had increased to four", commented CEO Per Norlén.
-
LakePharma and NJ Bio Form Strategic Alliance to Provide Streamlined Antibody-Drug Conjugate Services
2/11/2020
LakePharma, Inc., the leading US-based biologics CRDMO, and NJ Biopharmaceuticals LLC (d/b/a NJ Bio), a CRO providing integrated chemistry and biology services, today announce the formation of a strategic alliance to offer streamlined antibody-drug conjugate (ADC) development solutions for the biotech
-
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer
2/10/2020
Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced updated results from the phase 1b/2 clinical trial EV-103 in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for treatment with cisplatin-based chemotherapy.
-
Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results
2/6/2020
ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $627.7 Million in 2019, Including $166.2 Million in the Fourth Quarter
-
Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
2/5/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), today announced the expansion of its senior management team with the appointments of Kristin Bedard, Ph.D., as Vice President of Immunobiology, and Brunilda Shtylla as Vice President of Business Development.